EC approves bimatoprost as first-line therapy

March 15, 2004

London-The European Commission (EC) has approved Allergan Inc.'s bimatoprost ophthalmic solution 0.03% (Lumigan) as a first-line therapy to reduce IOP in chronic open-angle glaucoma and ocular hypertension.